Li Jian, Neubauer Peter
Chair of Bioprocess Engineering, Department of Biotechnology, Technische Universität Berlin, Ackerstraße76, ACK24, D-13355 Berlin, Germany.
Chair of Bioprocess Engineering, Department of Biotechnology, Technische Universität Berlin, Ackerstraße76, ACK24, D-13355 Berlin, Germany.
N Biotechnol. 2014 Dec 25;31(6):579-85. doi: 10.1016/j.nbt.2014.03.006. Epub 2014 Apr 1.
Nonribosomal peptides (NRPs) and polyketides (PKs) are two classes of natural products with numerous bioactivities such as antiviral, antimicrobial and anticancer activity. However, pharmaceutical applications of these products are often impeded because many native producers are difficult to cultivate or show a low productivity. Over the last decade, with the development of synthetic biology and metabolic engineering, more and more bioactive natural products including NRPs and PKs have been heterologously produced using easy-to-handle surrogate microbes. In this process, the full biosynthetic pathway for the production of a target compound is first identified and isolated from the native producer, and then reconstituted in a well-characterized and easily culturable heterologous producer like Escherichia coli. Thereafter, the productivity could be rationally improved through multiple strategies from strain to bioprocess optimization. This review summarizes the endeavors and progresses made in the heterologous production of NRPs, PKs and NRP/PK hybrids using E. coli as a robust whole-cell factory in recent years.
非核糖体肽(NRPs)和聚酮化合物(PKs)是两类具有多种生物活性的天然产物,如抗病毒、抗菌和抗癌活性。然而,这些产品的药物应用常常受到阻碍,因为许多天然生产者难以培养或产量较低。在过去十年中,随着合成生物学和代谢工程的发展,越来越多包括NRPs和PKs在内的生物活性天然产物已通过易于操作的替代微生物进行异源生产。在此过程中,首先从天然生产者中鉴定并分离出目标化合物的完整生物合成途径,然后在特征明确且易于培养的异源生产者(如大肠杆菌)中进行重构。此后,可以通过从菌株到生物过程优化的多种策略合理提高产量。本综述总结了近年来利用大肠杆菌作为强大的全细胞工厂异源生产NRPs、PKs和NRP/PK杂合物所取得的努力和进展。